… small-cell lung cancer who had striking responses to gefitinib had somatic mutations in the
EGFR gene that would indicate the essential role of the EGFR signaling pathway in the tumor. …

… are associated with responsiveness to gefitinib in Taiwanese lung cancer patients, we
also did mutational study in tumors from 16 patients who had received gefitinib treatment as a …

… human tumors (8). These results indicate that gefitinib has potential for treating lung cancers
… growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. …

… predict responsiveness of advanced NSCLCs to gefitinib. Statistical analysis of expression
profiles in 17 clinical samples identified dozens of genes that were differentially expressed …

… with EGFR-mutant, gefitinib-responsive, advanced non–small-cell lung cancer who had a …
treatment with gefitinib. The DNA sequence of the EGFR gene in his tumor biopsy specimen at …

… vitro sensitivity to gefitinib correlates with distinct clinical responsiveness to gefitinib in various
… growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib …

… a 5-year survival rate) for lung cancer in 2002 were 15% for … of lung cancers are of the
non-small-cell lung cancer (NSCLC… -small cell lung cancers related to gefitinib responsiveness in …

… were the only two significant predictors for gefitinib responsiveness by this analysis (Table
4). These are similar to previous reports by other groups [15], [19], [20], [26]. It was somewhat …

… (NSCLC) [1–3]. To date, however, only a few EGFR mutations have been detected in other
solid tumors [4]. We now describe a patient with gefitinib-responsive small-cell lung cancer (…

… Moreover, EGFR gene copy number and, potentially, also EGFR intron 1 polymorphism
could aid in better prediction of EGFR TKI responsiveness in advanced NSCLC. …